饮酒、吸烟与心血管疾病关系的多变量孟德尔随机化研究
研究发现遗传预测的饮酒与高密度脂蛋白胆固醇升高、甘油三酯降低和血压升高相关,但未发现对心血管结局的保护作用;吸烟在调整饮酒后仍与多种心血管疾病风险增加相关。
要点
- 遗传预测的饮酒与HDL-C升高、TRG降低和血压升高相关,但未显示心血管保护作用。
- 调整饮酒后,吸烟仍与心肌梗死、冠心病、心衰和大动脉粥样硬化风险增加相关。
- 饮酒对心肌梗死和冠心病的影响在调整吸烟后减弱,提示混杂效应。
核心结论
- 未发现遗传预测的饮酒对心血管结局有保护作用。
- 吸烟是多种心血管疾病的独立风险因素,即使调整饮酒后仍显著。
主要发现
- 遗传预测饮酒与HDL-C(beta 0.40, 95%CI 0.04-0.47, P=1.72×10-28)、自动化收缩压(beta 0.11, 95%CI 0.03-0.18, P=4.72×10-3)和舒张压(beta 0.09, 95%CI 0.03-0.16, P=5.24×10-3)正相关,与TRG负相关(beta -0.23, 95%CI -0.30至-0.15, P=4.69×10-10)。
- 遗传预测吸烟与TRG升高相关(beta 0.097, 95%CI 0.014-0.027, P=6.59×10-12)。
- 饮酒与MI(OR 1.24, 95%CI 1.03-1.50, P=0.02)和CHD(OR 1.21, 95%CI 1.01-1.45, P=0.04)风险增加相关,但调整吸烟后减弱;与冠状动脉粥样硬化仍相关(OR 1.02, 95%CI 1.01-1.03, P=5.56×10-4)。
- 调整饮酒后,吸烟与MI(OR 1.84, 95%CI 1.43-2.37, P=2.0×10-6)、CHD(OR 1.64, 95%CI 1.28-2.09, P=8.07×10-5)、HF(OR 1.61, 95%CI 1.32-1.95, P=1.9×10-6)和大动脉粥样硬化(OR 2.4, 95%CI 1.41-4.07, P=0.003)相关。
- 在FinnGen队列中重复验证了吸烟与MI(OR 1.77, 95%CI 1.10-2.84, P=0.02)、HF(OR 1.67, 95%CI 1.14-2.46, P=0.008)和PAD(OR 2.35, 95%CI 1.38-4.01, P=0.002)的关联。
临床怎么用
- 生活方式干预(减少饮酒和戒烟)可能降低整体心血管疾病风险。
- 饮酒对心血管的影响可能通过HDL-C、TRG和血压等途径介导,需进一步研究。
局限性
- 可能存在未测量混杂因素偏倚。
- 摘要级孟德尔随机化无法探究饮酒与CVD风险之间的非线性关系。
- UK Biobank数据对其他人群的普适性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alcohol consumption and smoking, 2 major risk factors for cardiovascular disease (CVD), often occur together. The objective of this study is to use a wide range of CVD risk factors and outcomes to evaluate potential total and direct causal roles of alcohol and tobacco use on CVD risk factors and events. METHODS AND FINDINGS: Using large publicly available genome-wide association studies (GWASs) (results from more than 1.2 million combined study participants) of predominantly European ancestry, we conducted 2-sample single-variable Mendelian randomization (SVMR) and multivariable Mendelian randomization (MVMR) to simultaneously assess the independent impact of alcohol consumption and smoking on a wide range of CVD risk factors and outcomes. Multiple sensitivity analyses, including complementary Mendelian randomization (MR) methods, and secondary alcohol consumption and smoking datasets were used. SVMR showed genetic predisposition for alcohol consumption to be associated with CVD risk factors, including high-density lipoprotein cholesterol (HDL-C) (beta 0.40, 95% confidence interval (CI), 0.04-0.47, P value = 1.72 × 10-28), triglycerides (TRG) (beta -0.23, 95% CI, -0.30, -0.15, P value = 4.69 × 10-10), automated systolic blood pressure (BP) measurement (beta 0.11, 95% CI, 0.03-0.18, P value = 4.72 × 10-3), and automated diastolic BP measurement (beta 0.09, 95% CI, 0.03-0.16, P value = 5.24 × 10-3). Conversely, genetically predicted smoking was associated with increased TRG (beta 0.097, 95% CI, 0.014-0.027, P value = 6.59 × 10-12). Alcohol consumption was also associated with increased myocardial infarction (MI) and coronary heart disease (CHD) risks (MI odds ratio (OR) = 1.24, 95% CI, 1.03-1.50, P value = 0.02; CHD OR = 1.21, 95% CI, 1.01-1.45, P value = 0.04); however, its impact was attenuated in MVMR adjusting for smoking. Conversely, alcohol maintained an association with coronary atherosclerosis (OR 1.02, 95% CI, 1.01-1.03, P value = 5.56 × 10-4). In comparison, after adjusting for alcohol consumption, smoking retained its association with several CVD outcomes including MI (OR = 1.84, 95% CI, 1.43, 2.37, P value = 2.0 × 10-6), CHD (OR = 1.64, 95% CI, 1.28-2.09, P value = 8.07 × 10-5), heart failure (HF) (OR = 1.61, 95% CI, 1.32-1.95, P value = 1.9 × 10-6), and large artery atherosclerosis (OR = 2.4, 95% CI, 1.41-4.07, P value = 0.003). Notably, using the FinnGen cohort data, we were able to replicate the association between smoking and several CVD outcomes including MI (OR = 1.77, 95% CI, 1.10-2.84, P value = 0.02), HF (OR = 1.67, 95% CI, 1.14-2.46, P value = 0.008), and peripheral artery disease (PAD) (OR = 2.35, 95% CI, 1.38-4.01, P value = 0.002). The main limitations of this study include possible bias from unmeasured confounders, inability of summary-level MR to investigate a potentially nonlinear relationship between alcohol consumption and CVD risk, and the generalizability of the UK Biobank (UKB) to other populations. CONCLUSIONS: Evaluating the widest range of CVD risk factors and outcomes of any alcohol consumption or smoking MR study to date, we failed to find a cardioprotective impact of genetically predicted alcohol consumption on CVD outcomes. However, alcohol was associated with and increased HDL-C, decreased TRG, and increased BP, which may indicate pathways through impact CVD risk, warranting further study. We found smoking to be a risk factor for many CVDs even after adjusting for alcohol. While future studies incorporating alcohol consumption patterns are necessary, our data suggest causal inference between alcohol, smoking, and CVD risk, further supporting that lifestyle modifications might be able to reduce overall CVD risk.
引用
- Rosoff DB, Davey Smith G, Mehta N, et al. Evaluating the relationship between alcohol consumption, tobacco use, and cardiovascular disease: A multivariable Mendelian randomization study. PLoS Med. 2020. PMID: 33275596. doi:10.1371/journal.pmed.1003410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。